China Pharma Holdings (CPHI) Return on Capital Employed (2011 - 2026)
China Pharma Holdings' (CPHI) quarterly Return on Capital Employed came in at 11.68% in Q1 2026, up 3531.0% YoY from 0.32% in Q1 2025, and up 42.3% on a QoQ basis from 20.24% in Q4 2025.
China Pharma Holdings (CPHI) Return on Capital Employed (2011 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 16 years of Return on Capital Employed data on file, last reported at 11.68% in Q1 2026.
- Quarterly Return on Capital Employed rose 3531.0% year-over-year to 11.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.68% (up 3531.0% YoY) and the FY2025 annual result came in at 20.84%, up 2220.0% from the prior year.
- Return on Capital Employed improved to 11.68% in Q1 2026, from 20.24% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.68% in Q1 2026 to a low of 83.42% in Q4 2022.
- A 5-year average of 41.12% and a median of 40.0% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 5453 bps — and 2023, when it surged 5315 bps.
- Tracing CPHI's Return on Capital Employed over 5 years: stood at 83.42% in 2022, then surged by 64 bps to 30.27% in 2023, then slumped by 65 bps to 50.1% in 2024, then jumped by 60 bps to 20.24% in 2025, then soared by 42 bps to 11.68% in 2026.
- The last three Return on Capital Employed figures came in at 11.68% (Q1 2026), 20.24% (Q4 2025), and 39.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.00 Bn | 43.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.78 Bn | 30.10 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.92 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.21 Bn | 19.54 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 41.33 Mn | 41.02 Mn | 83,566.00 | -11.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.68% |
| Dec 31, 2025 | -20.24% |
| Sep 30, 2025 | -39.63% |
| Jun 30, 2025 | -42.24% |
| Mar 31, 2025 | -46.99% |
| Dec 31, 2024 | -50.10% |
| Sep 30, 2024 | -50.28% |
| Jun 30, 2024 | -40.00% |
| Mar 31, 2024 | -30.85% |
| Dec 31, 2023 | -30.27% |
| Sep 30, 2023 | -32.30% |
| Jun 30, 2023 | -45.32% |
| Mar 31, 2023 | -53.73% |
| Dec 31, 2022 | -83.42% |
| Sep 30, 2022 | -68.32% |
| Jun 30, 2022 | -27.90% |
| Mar 31, 2022 | -25.75% |
| Dec 31, 2021 | -28.88% |
| Sep 30, 2021 | -38.48% |
| Jun 30, 2021 | -45.49% |